Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 2, 2012, Pages 138-143

  Stangier, Joachim ^a   Feuring, Martin ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

coagulation time; dabigatran concentration measurement; dabigatran etexilate; direct thrombin inhibitor; HEMOCLOT Thrombin Inhibitors assay; Pradaxa

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE;

ACCURACY; ANTICOAGULATION; ARTICLE; CALCULATION; CALIBRATION; DILUTION; DRUG BLOOD LEVEL; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; THROMBIN TIME;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; CALIBRATION; HUMANS;

EID: 84856593171     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834f1b0c     Document Type: Article

References (10)

1. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran, a new oral direct thrombin inhibitor in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303. (Pubitemid 47283865)
2. Hazlewood KA, Weiland CM. Advances in oral anticoagulants: focus on dabigatran etexilate. Expert Rev Clin Pharmacol 2010; 3:727-737.
3. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103:62-70.
4. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.
5. HYPHEN BioMed. (2009). Hemoclot1 Thrombin Inhibitors (Kit Insert). http://www.coachrom.com/docs/hyp/CK002L.pdf. [Accessed 15 September 2011]
6. Tholen DW, Kallner A, Kennedy JW, Krouwer JS, Meier K. Evaluation of precision performance of quantitative measurement methods; Approved Guideline-Second Edition (2004). NCCLS document EP5-A2 (ISBN 1-56238-542-9). http://www.clsi.org/source/orders/free/ep5-a2.pdf. (Accessed 15 September 2011).
7. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23:312-328. (Pubitemid 43237862)
8. Gardiner C, Adcock DM, Carrington LR, Marchant KK, Marlar RA, McGlasson DL, et al. Protocol for the evaluation, validation, and implementation of coagulometers (2008). NCCLS document H57-A (ISBN 1-56238-656-5). http://www.clsi.org/source/orders/free/h57-A. pdf. (Accessed 15 September 2011).
9. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-160. (Pubitemid 29425900)
10. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47:47-59. (Pubitemid 350260888)